How is exenatide dosed?
| Product | Supplied as | Label dose and schedule |
|---|---|---|
| Byetta 5 mcg pen1 | 300 mcg/1.2 mL (250 mcg/mL), 60 doses | 5 mcg twice daily to start |
| Byetta 10 mcg pen1 | 600 mcg/2.4 mL (250 mcg/mL), 60 doses | 10 mcg twice daily after 1 month, based on clinical response |
| Bydureon BCise autoinjector2 | 2 mg exenatide in 0.85 mL suspension, single dose | 2 mg once every 7 days |
How exenatide is supplied
The table is set at the top of the page
The Byetta label says not to transfer the medication to a syringe; no label gives a U-100 syringe use, and the only sourced concentration is 250 mcg/mL.1 The Bydureon BCise label says the autoinjector is taken out of the refrigerator 15 minutes before mixing, then mixed by shaking vigorously for at least 15 seconds; its ingredients list gives a powder and a liquid diluent.2 Mixing steps for the older Bydureon kit are not given.
Three exenatide labels were searched, all Byetta or its generic pen; no powder or compounded exenatide label, trial or stability data is held.
Label doses, step-up and timing
The Byetta label, for adults with type 2 diabetes, gives 5 mcg twice daily as the starting dose, increased to 10 mcg twice daily after 1 month based on clinical response.1 It gives the wait of 1 month before the increase as a way to reduce the risk of gastrointestinal adverse reactions.1 The label gives the timing as within 60 minutes before the morning and evening meals, about 6 hours or more apart, and not after a meal.1
The Bydureon BCise label, for adults and children 10 years and older with type 2 diabetes, gives 2 mg once every 7 days, at any time of day, with or without meals.2
Doses in the named trials
| Trial | Dose and schedule | People | Length |
|---|---|---|---|
| EXSCEL (Holman)34 | Extended-release 2 mg once weekly or placebo | 14,752 patients with type 2 diabetes, with or without previous cardiovascular disease: 7356 exenatide, 7396 placebo | Median follow-up 3.2 years |
| Parkinson's, single centre (Athauda)5 | 2 mg once weekly or placebo, in addition to regular medication | 62 patients with moderate Parkinson's disease: 32 exenatide, 30 placebo | 48 weeks, then 12-week washout |
| Parkinson's, UK phase 3 trial (Vijiaratnam, 2025)6 | Extended-release 2 mg once per week by pen or placebo | 194 participants aged 25-80 years with Parkinson's disease, at Hoehn and Yahr stage 2·5 or less when on dopaminergic treatment: 97 per arm | 96 weeks |
An expression of concern is listed for the UK phase 3 Parkinson's trial.
Where it is injected
The Byetta label gives subcutaneous injection in the thigh, abdomen or upper arm, with sites rotated.1 Its patient instructions say not to inject into a muscle or vein.1 The Bydureon BCise label gives subcutaneous injection in the abdomen, thigh or upper arm region immediately after the autoinjector is prepared, with a different injection site each week when injecting in the same region.2
Storage before and after first use
The Byetta label gives storage before first use in the original carton in a refrigerator at 36°F to 46°F (2°C to 8°C), protected from light.1 After first use it gives not above 77°F (25°C), not frozen, with the pen discarded 30 days after first use even if some drug remains.1 The Bydureon BCise label gives storage flat, in the original package, protected from light, in the refrigerator at 36°F to 46°F (2°C to 8°C), with up to 4 weeks in total at room temperature not above 86°F (30°C).2
Frequently asked questions
What does the label say about a missed dose?
The Byetta label says the next scheduled dose is taken as prescribed, with no extra dose.1 The Bydureon BCise label says to give a missed dose as soon as noticed if the next scheduled dose is due at least 3 days later.2 If the next scheduled dose is due 1 or 2 days later, the label says the missed dose is not given and the next scheduled dose is taken as usual.2
Can the weekly day of Bydureon BCise be changed?
The Bydureon BCise label says the day of weekly administration can be changed if necessary, as long as the last dose was 3 or more days before the new day.2
Is there a labelled exenatide dose for weight loss?
The Byetta label's indication is glycemic control in adults with type 2 diabetes, and it does not list weight loss.1 A single-center, placebo-controlled trial (Basolo) randomised 80 healthy, non-diabetic volunteers with obesity to exenatide 10 μg twice daily or placebo and found no difference in body weight versus placebo.7 Apart from that study, no label or human trial with weight loss as the indication is held here.
References
- DailyMed. These highlights do not include all the information needed to use BYETTA safely and effectively. See full prescribing information for BYETTA. BYETTA® (exenatide) injection, for subcutaneous use Initial U.S. Approval: 2005. 2025. dailymed.nlm.nih.gov
- FDA. Bydureon BCise (exenatide extended-release) injectable suspension. Prescribing information. 2025. accessdata.fda.gov
- PMC. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. 2017. pmc.ncbi.nlm.nih.gov
- ClinicalTrials.gov. NCT01144338: Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus. 2018. clinicaltrials.gov
- PMC. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. 2017. pmc.ncbi.nlm.nih.gov
- PubMed. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. 2025. pubmed.ncbi.nlm.nih.gov
- PMC. Exenatide has a Pronounced Effect on Energy Intake but not Energy Expenditure in Non-Diabetic Subjects with Obesity: a Randomized, Double-blind, Placebo-Controlled Trial. 2018. pmc.ncbi.nlm.nih.gov